Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by Dana-Farber Cancer Institute
Sponsor:
Collaborators:
Miltenyi Biotec GmbH
Prometheus Laboratories
Information provided by (Responsible Party):
John Koreth, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01937468
First received: August 30, 2013
Last updated: June 27, 2014
Last verified: June 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: July 2018
  Estimated Primary Completion Date: November 2016 (Final data collection date for primary outcome measure)